代谢组学证据提示部分1组肺动脉高压与射血分数保留的心力衰竭存在生物学重叠
本研究比较了1组肺动脉高压患者按HFpEF-ABA概率分层后的血清/跨肺代谢组。高HFpEF概率组(n=131)较低概率组(n=62)有207种代谢物显著升高、231种显著降低,且代谢组变化与临床HFpEF(n=240)重叠,支持两种形式PH的生物学重叠。
要点
- 1组PH高HFpEF概率者代谢组独特:色氨酸-犬尿氨酸通路增强、血清素降低。
- 该组亚油酸、精氨酸、高精氨酸等前列腺素和一氧化氮前体降低。
- 代谢组变化与临床HFpEF重叠,提示1组PH与HFpEF存在生物学重叠。
核心结论
- 1组PH高HFpEF概率患者具有独特代谢组,以色氨酸-犬尿氨酸通路分解增强为特征。
- 这些代谢组变化与临床HFpEF相当,支持1组PH与HFpEF的生物学重叠。
研究设计与样本
- 将1组PH患者按HFpEF-ABA概率分为低(<25%)和高(⩾75%)两组,并设健康对照和临床HFpEF对照。
- 比较静脉和跨肺代谢组;高概率组n=131,低概率组n=62,临床HFpEF n=240,对照n=85。
主要发现
- 高HFpEF概率组较低概率组有207种代谢物显著增加(FDR P<0.05且倍数变化>1,n=193,t检验)。
- 高HFpEF概率组有231种代谢物显著降低(FDR P<0.05且倍数变化<1,n=193,t检验)。
- 高HFpEF概率组色氨酸代谢增强,下游犬尿氨酸代谢物浓度更高、血清素浓度更低(FDR P<0.002,n=193,t检验)。
- 亚油酸、精氨酸和高精氨酸在高HFpEF概率组均更低(FDR P<0.03,n=193,t检验)。
- 高HFpEF概率组代谢组与临床HFpEF重叠,但相对对照异常(P<0.0001,n=456,t检验)。
关键数值与推荐
- HFpEF-ABA概率低定义为<25%,高定义为⩾75%。
- 代谢物显著差异标准:FDR P<0.05且倍数变化>1或<1(n=193,t检验)。
临床怎么用
- 对1组PH患者可考虑评估HFpEF概率,高概率者可能存在与HFpEF重叠的代谢特征。
- 色氨酸-犬尿氨酸通路、血清素及前列腺素/一氧化氮前体改变或有助于识别1组PH中的HFpEF样亚群。
局限性
- 大多数代谢物无跨肺摄取/释放差异证据,提示可能为非肺来源(血清素交互P=0.04、犬尿氨酸交互P=0.03,n=433,混合模型)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: A subset of patients with group 1 pulmonary hypertension (PH) have superimposed left heart abnormalities with unclear metabolic implications. Objectives: To compare serum/transpulmonary metabolome between group 1 PH stratified by heart failure with preserved ejection fraction (HFpEF) probability. Methods: Patients with group 1 PH were stratified into low (<25%) and high (⩾75%) HFpEF-ABA (age, body mass index, and atrial fibrillation) probability, with healthy control subjects and subjects with clinical HFpEF used for comparison of venous and transpulmonary metabolomics. Measurements and Main Results: Group 1 PH + high HFpEF probability (n = 131) was associated with a significant increase in 207 metabolites (false discovery rate [FDR] P < 0.05 and fold change >1) (n = 193, t test) and a significant decrease in 231 metabolites (FDR P < 0.05 and fold change <1) (n = 193, t test) compared with group 1 PH + low HFpEF probability (n = 62). Group 1 PH + high HFpEF probability was associated with enhanced tryptophan metabolism with higher downstream kynurenine metabolite concentrations and lower serotonin concentrations (FDR P < 0.002 for all, n = 193, t test). Linoleate (precursor to arachidonic acid and prostaglandins) and arginine and homoarginine (precursors to nitric oxide) were all lower in group 1 PH + high HFpEF probability (FDR P < 0.03 for all, n = 193, t test). Metabolome changes in group 1 PH + high HFpEF probability overlapped with clinical HFpEF (n = 240) but were abnormal relative to control subjects (n = 85) (P < 0.0001 for all, n = 456, t test). There was no evidence of differential transpulmonary uptake/release of most metabolites, suggesting probable nonpulmonary origin (except for serotonin, interaction P = 0.04; and kynurenine, interaction P = 0.03; n = 433, mixed model). Conclusions: Patients with group 1 PH + high HFpEF probability have a unique metabolome characterized by enhanced tryptophan-kynurenine pathway breakdown, deficiency of amino acids (such as glycine and serine), lower serotonin, and decreased prostaglandin and nitric oxide precursors. Despite fulfilling clinical criteria for group 1 PH, these metabolome changes were comparable with clinical HFpEF, supporting biological overlap between these two forms of PH.
引用
- Reddy YNV, Asokan AK, Frantz RP, et al. Metabolomic Evidence of Biological Overlap with Heart Failure with Preserved Ejection Fraction in a Subset of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2025. PMID: 40504754. doi:10.1164/rccm.202501-0034OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。